Understanding T Cell Roles in Chronic Graft Versus Host Disease
Defining the T Cell Mediators of Clinical Response in Chronic GVHD
This study is looking at how certain immune cells called T cells affect chronic graft versus host disease (cGVHD) after stem cell transplants, and it aims to find out why some patients respond better to treatments than others, so we can improve care for everyone dealing with this condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10914139 on NIH RePORTER |
What this research studies
This research investigates how T cells contribute to chronic graft versus host disease (cGVHD), a serious condition that can occur after stem cell transplants. The project aims to identify immune profiles in patients that predict their response to treatment and to understand why some patients respond well while others do not. By analyzing immune pathways and treatment outcomes, the research seeks to improve therapeutic strategies for cGVHD. Patients may be monitored over time to gather data on their immune responses and treatment effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone hematopoietic stem cell transplantation and are experiencing symptoms of chronic graft versus host disease.
Not a fit: Patients who have not undergone stem cell transplantation or do not have chronic graft versus host disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from chronic graft versus host disease.
How similar studies have performed: Previous research has shown promise in understanding immune responses in cGVHD, but this project aims to provide more personalized insights, making it a novel approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Kean, Leslie S — Dana-Farber Cancer Inst
- Study coordinator: Kean, Leslie S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.